1. NOACs in CAD

2. Atherothrombosis and Residual Risk

3. "Stable" Patients Remain at Risk for CV Events

4. Pathobiology of Atherothrombosis

5. Thrombotic Pathway More Than Antiplatelet Monotherapy

6. ATLAS ACS 2--TIMI 51

7. COMPASS Design 27,395 Subjects, 602 Sites, 33 Countries

8. Clinician Awareness Rivaroxaban Dosing

9. COMPASS Population

10. COMPASS CAD Inclusion Criteria

11. COMPASS Exclusion Criteria

12. COMPASS Primary Endpoint

13. COMPASS MACE*

14. COMPASS Major Bleeding*

15. FDA New Indication for Rivaroxaban, October 2018

16. Individual Risk Assessment

17. COMPASS Primary Endpoint Results Were Consistent Across All Subgroups

18. Risk Scores in CAD

19. TIMI Secondary Prevention Risk Score

20. Predictors of Major Adverse Limb Events From COMPASS

21. Selecting Appropriate Patients High-Risk Subgroups

22. Conclusions

23. Abbreviations

24. Abbreviations (cont)